miRNA Scientific — Stock, Pipeline & Market Cap

Is this your company? Claim your profile to update info and connect with investors.

Private Company

Funding information not available

Overview

MiRNA Scientific is a private, commercial-stage diagnostics company developing a novel platform for cancer detection and management. Its core technology analyzes small non-coding RNAs (sncRNAs) from urinary exosomes to provide molecular evidence of prostate cancer and classify its risk aggressiveness. The company's initial product, the miR Sentinel™ Prostate Cancer Test, aims to address the significant shortcomings of the current prostate cancer screening standard of care, which relies on inaccurate PSA tests and invasive biopsies. MiRNA Scientific positions its solution as a scalable, efficient, and patient-friendly alternative that can improve early detection and reduce unnecessary procedures.

OncologyUrology

Technology Platform

Proprietary miR Disease Management Platform® that isolates and analyzes small non-coding RNAs (sncRNAs) from urinary exosomes to detect and classify cancer at the molecular level.

Opportunities

The company addresses a massive unmet need in prostate cancer screening, where the current standard of care is invasive and inefficient, leading to patient avoidance and unnecessary procedures.

Its non-invasive, scalable platform has the potential to significantly reduce healthcare costs for payors and employers while improving patient experience and outcomes through earlier, more accurate detection.

Risk Factors

Key risks include the challenge of changing entrenched clinical practices and securing insurance reimbursement for a novel test.

The company also faces intense competition in the liquid biopsy space and must continually validate its technology's accuracy in large, diverse populations to maintain clinical credibility.

Competitive Landscape

MiRNA Scientific competes in the non-invasive cancer detection space, specifically against other liquid biopsy tests for prostate cancer (e.g., ExoDx Prostate, SelectMDx) and the broader standard of care (PSA, MRI, biopsy). Its primary differentiation is its focus on sncRNA from urine, claiming a unique molecular insight not reliant on traditional clinical factors.

More companies in Diagnostics & Precision Medicine →More companies in United States →